1 High-Yield Dividend Stock That's Too Cheap to Ignore

Key Points
Bristol Myers Squibb operates in a defensive industry that can navigate challenging periods fairly well.
Despite some recent headwinds, the company could perform well over the long run.
The stock offers a high yield and consistent dividend growth.
- 10 stocks we like better than Bristol Myers Squibb ›
Investors are dealing with significant market volatility amid trade wars, geopolitical tensions, etc. Some are worried about inflation rising, a potential market downturn, or perhaps even a recession. In an environment like this, it helps to invest in companies that can perform relatively well regardless of market or economic conditions. Corporations with excellent dividend programs are especially worth a second look right now. In that spirit, let's consider a solid dividend stock whose shares look attractive: Bristol Myers Squibb (NYSE: BMY).
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
It could be a steady wealth compounder
Bristol Myers is a leading company in a defensive pharmaceutical industry that's built to handle the toughest environments. Not only are lifesaving drugs some of the ultimate "essential goods," but because of the nature of the industry, and the fact that third-party payers foot much of the bill for prescription medicines, demand remains fairly consistent through good and bad economic times.
Bristol Myers' portfolio spans several areas, including oncology -- where it is a leader -- immunology, rare diseases, and others. The company has encountered some troubles in recent years, particularly due to patent cliffs. Revenue growth hasn't been strong as a result. In the fourth quarter, Bristol Myers' sales increased by just 1% year over year to $12.5 billion.
However, Bristol Myers has an innovative engine that should allow it to launch newer products and eventually move beyond generic or biosimilar competition for older drugs. The company is already slowly doing so, thanks to a growth portfolio mostly composed of therapies approved since 2019 or so. These include a new, subcutaneous formulation of Bristol Myers' famous and highly successful oncology franchise, Opdivo.
Even with the old version set to lose patent exclusivity in a couple of years, this franchise, which has been one of Bristol Myers' growth drivers for a while, should continue contributing. How is the company's growth portfolio performing? In the fourth quarter, it reported $7.4 billion in sales, up 16% year over year. Top-line growth should bounce back as the impact from off-patent medicines on the company's financial results continues to fade and newer products gain more traction and earn label expansions
So, Bristol Myers should be in good shape, even in a highly volatile market. What about the company's dividend? Bristol Myers offers a juicy forward yield of 4.2%, which is well above the S&P 500's average of 1.2%. The company has increased its dividends by 65.8% over the past 10 years, and its cash payout ratio of 39.3% leaves ample room for more dividend growth.
Lastly, Bristol Myers' valuation looks reasonable right now. The company is trading at 9.5x forward earnings, well below the healthcare sector's forward price-to-earnings average of 17.1. In short, Bristol Myers is a stable company capable of delivering strong financial results over the long term -- even as the market and the economy experience downturns -- while rewarding shareholders with a growing dividend. In today's precarious environment, that may be exactly what the doctor ordered.
Should you buy stock in Bristol Myers Squibb right now?
Before you buy stock in Bristol Myers Squibb, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*
Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 21, 2026.
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.